First AD

Second AD

Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

A New Wave of Progress in the Treatment of Renal Cell Carcinoma: Highlights from ASCO GU 2023 and Beyond

Peer Exchange

Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.

Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

Screenshot 2023-03-06 at 7.58.00 PM.png

Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

Treatment Approaches for Patients with RCC and Bone Metastases

Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

Updates in the Adjuvant Treatment of Metastatic RCC

Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC

Preferred Treatment Regimens for Refractory RCC

Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

Genetic Counseling for Patients with Non-Clear Cell RCC